| Stephen L Miller, MD | |
|
1840 Amherst St, Winchester, VA 22601-2808 | |
| (540) 536-8750 | |
| Not Available |
| Full Name | Stephen L Miller |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 43 Years |
| Location | 1840 Amherst St, Winchester, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336119460 | NPI | - | NPPES |
| 1336119460 | Medicaid | WV | |
| 7247427 | Medicaid | VA | |
| 6688-0007 | Other | VA | CAREFIRST |
| 7237839 | Medicaid | VA | |
| 7237855 | Medicaid | VA | |
| 7237871 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 0101039422 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fauquier Hospital | Warrenton, VA | Hospital |
| Warren Memorial Hospital | Front royal, VA | Hospital |
| Winchester Medical Center | Winchester, VA | Hospital |
| Shenandoah Memorial Hospital | Woodstock, VA | Hospital |
| Page Memorial Hospital, Inc | Luray, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Winchester Radiologists Pc | 7113915281 | 32 |
| Winchester Radiologists Pc | 7113915281 | 32 |
News Archive
Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced data from the Phase III PRIMA study.
The bio-pharmaceutical marketplace – and the oncology therapeutic area in particular – continues to evolve as new medicines and technologies create valuable market opportunities. It's in this competitive and challenging environment that organizations with new oncology products are scrutinizing their strategies and tactics to support market education.
The Next-Generation Drug Discovery Community will unite researchers at Cambridge University and MIT with partners from the information technology, pharmaceutical and biotechnology industries to find ways to speed up development of the next generation of drugs-particularly those that treat diseases with complex causes such as cancers, arthritis, multiple sclerosis and diabetes.
Physicians have known for decades that many premature babies suffer respiratory problems stemming from insufficiency of a lung substance called surfactant during their first few weeks of life.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
› Verified 1 days ago
| Entity Name | Shenandoah Memorial Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952417735 PECOS PAC ID: 2466360375 Enrollment ID: O20040115001156 |
News Archive
Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced data from the Phase III PRIMA study.
The bio-pharmaceutical marketplace – and the oncology therapeutic area in particular – continues to evolve as new medicines and technologies create valuable market opportunities. It's in this competitive and challenging environment that organizations with new oncology products are scrutinizing their strategies and tactics to support market education.
The Next-Generation Drug Discovery Community will unite researchers at Cambridge University and MIT with partners from the information technology, pharmaceutical and biotechnology industries to find ways to speed up development of the next generation of drugs-particularly those that treat diseases with complex causes such as cancers, arthritis, multiple sclerosis and diabetes.
Physicians have known for decades that many premature babies suffer respiratory problems stemming from insufficiency of a lung substance called surfactant during their first few weeks of life.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
› Verified 1 days ago
| Entity Name | Page Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326040684 PECOS PAC ID: 8426951203 Enrollment ID: O20040129000420 |
News Archive
Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced data from the Phase III PRIMA study.
The bio-pharmaceutical marketplace – and the oncology therapeutic area in particular – continues to evolve as new medicines and technologies create valuable market opportunities. It's in this competitive and challenging environment that organizations with new oncology products are scrutinizing their strategies and tactics to support market education.
The Next-Generation Drug Discovery Community will unite researchers at Cambridge University and MIT with partners from the information technology, pharmaceutical and biotechnology industries to find ways to speed up development of the next generation of drugs-particularly those that treat diseases with complex causes such as cancers, arthritis, multiple sclerosis and diabetes.
Physicians have known for decades that many premature babies suffer respiratory problems stemming from insufficiency of a lung substance called surfactant during their first few weeks of life.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
› Verified 1 days ago
| Entity Name | Warren Memorial Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164442281 PECOS PAC ID: 2365330347 Enrollment ID: O20040310000516 |
News Archive
Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced data from the Phase III PRIMA study.
The bio-pharmaceutical marketplace – and the oncology therapeutic area in particular – continues to evolve as new medicines and technologies create valuable market opportunities. It's in this competitive and challenging environment that organizations with new oncology products are scrutinizing their strategies and tactics to support market education.
The Next-Generation Drug Discovery Community will unite researchers at Cambridge University and MIT with partners from the information technology, pharmaceutical and biotechnology industries to find ways to speed up development of the next generation of drugs-particularly those that treat diseases with complex causes such as cancers, arthritis, multiple sclerosis and diabetes.
Physicians have known for decades that many premature babies suffer respiratory problems stemming from insufficiency of a lung substance called surfactant during their first few weeks of life.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
› Verified 1 days ago
| Entity Name | Winchester Radiologists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235123977 PECOS PAC ID: 7113915281 Enrollment ID: O20040505001553 |
News Archive
Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced data from the Phase III PRIMA study.
The bio-pharmaceutical marketplace – and the oncology therapeutic area in particular – continues to evolve as new medicines and technologies create valuable market opportunities. It's in this competitive and challenging environment that organizations with new oncology products are scrutinizing their strategies and tactics to support market education.
The Next-Generation Drug Discovery Community will unite researchers at Cambridge University and MIT with partners from the information technology, pharmaceutical and biotechnology industries to find ways to speed up development of the next generation of drugs-particularly those that treat diseases with complex causes such as cancers, arthritis, multiple sclerosis and diabetes.
Physicians have known for decades that many premature babies suffer respiratory problems stemming from insufficiency of a lung substance called surfactant during their first few weeks of life.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephen L Miller, MD Po Box 880, Lima, OH 45802-0880 Ph: (866) 482-5419 | Stephen L Miller, MD 1840 Amherst St, Winchester, VA 22601-2808 Ph: (540) 536-8750 |
News Archive
Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced data from the Phase III PRIMA study.
The bio-pharmaceutical marketplace – and the oncology therapeutic area in particular – continues to evolve as new medicines and technologies create valuable market opportunities. It's in this competitive and challenging environment that organizations with new oncology products are scrutinizing their strategies and tactics to support market education.
The Next-Generation Drug Discovery Community will unite researchers at Cambridge University and MIT with partners from the information technology, pharmaceutical and biotechnology industries to find ways to speed up development of the next generation of drugs-particularly those that treat diseases with complex causes such as cancers, arthritis, multiple sclerosis and diabetes.
Physicians have known for decades that many premature babies suffer respiratory problems stemming from insufficiency of a lung substance called surfactant during their first few weeks of life.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
› Verified 1 days ago
Yusuf Tahiri Akpolat, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-8750 | |
Dr. Joseph Anthony Couvillon, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-8750 Fax: 540-536-8827 | |
Christine E. Huxol, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-8750 Fax: 540-536-8827 | |
Kiarash Jahed, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-8750 Fax: 540-536-8827 | |
Dr. David Kent Harry, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-8750 | |
Dr. Curtis Jeffrey Thwing, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-8750 | |
Nabeel Arastu, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-8750 |